Results

Total Results: 3,085 records

Showing results for "drug".

161. Weighted Summary Statistics: PUF Commercial Inpatient File (Version 2) (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/data/SyH-DR-PUF-Summary-Statistics-Commercial-Inpatient-Weighted.pdf
     September 26, 2023 - 33,400 0.35 237,354 2.49 86: Neuropsychiatry 581 0.01 237,935 2.49 87: All other suppliers (e.g., drug … G0008-G9987: Procedures/Professional Services 14,124 0.15 9,223,219 96.71 H0001-H2037: Alcohol and Drug … G0008-G9987: Procedures/Professional Services 4,868 0.05 9,283,520 97.34 H0001-H2037: Alcohol and Drug … G0008-G9987: Procedures/Professional Services 2,368 0.02 9,328,424 97.82 H0001-H2037: Alcohol and Drug … G0008-G9987: Procedures/Professional Services 1,434 0.02 9,360,427 98.15 H0001-H2037: Alcohol and Drug

162. Appendix C. Glossary and Abbreviations | Agency for Healthcare Research and Quality
     www.ahrq.gov/research/findings/final-reports/prospectscare/prospectsapc.html
     April 01, 2020 - Code (NDC) Directory —The Drug Listing Act of 1972 requires registered drug establishments to provide … (See Section 510 of the Federal Food, Drug, and Cosmetic Act (Act) (21 U.S.C. § 360)). … Drug products are identified and reported using a unique, three-segment number, called the National Drug … vocabularies commonly used in pharmacy management and drug interaction software, including those of … Food and Drug Administration, http://www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm .

163. Weighted Summary Statistics: PUF Medicaid Outpatient File (Version 2) (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/data/SyH-DR-PUF-Summary-Statistics-Medicaid-Outpatient-Weighted.pdf
     September 26, 2023 - 126,308,923 82.19 86: Neuropsychiatry 16,608 0.01 126,325,532 82.20 87: All other suppliers (e.g., drug … -G9987: Procedures/Professional Services 6,067,332 3.95 146,398,883 95.27 H0001-H2037: Alcohol and Drug … -G9987: Procedures/Professional Services 1,517,656 0.99 150,385,574 97.86 H0001-H2037: Alcohol and Drug … G0008-G9987: Procedures/Professional Services 8,439 0.01 153,625,864 99.97 H0001-H2037: Alcohol and Drug … G0008-G9987: Procedures/Professional Services 5,477 0.00 153,641,490 99.98 H0001-H2037: Alcohol and Drug

164. Number of Newborns with Neonatal Abstinence Syndrome Continued To Increase Through 2016 | Agency for Healthcare Research and Quality
     www.ahrq.gov/data/infographics/neonatal-abstinence-syndrome-2016.html
     July 01, 2019 - Text Description: The number of babies born each year with withdrawal symptoms from their mother’s drug … In 2016, more than 25,000 babies were born with withdrawal symptoms from drug dependence compared with

165. AHRQ's Effective Health Care Guides Used in Omnicare's Pharmacies and Facilities | Agency for Healthcare Research and Quality
     www.ahrq.gov/news/newsroom/case-studies/coe0807.html
     October 01, 2014 - antipsychotic drugs is always "a balancing act," Erwin notes, "to use the lowest dose possible, if a drug … In addition to the antipsychotic drug guide, Omnicare also uses the EHC guides on Medications for Adults … Evaluate and document the potential contribution of drug therapy to unanticipated changes in the resident's

166. Final Progress Report: The Effect of EMR on Medication Safety: A SPUR-Net Study (pdf file)
     www.ahrq.gov/sites/default/files/2024-01/kuo-report.pdf
     January 01, 2024 - including selection, dose, route of administration, frequency, and directions)  Failure to detect adverse drug-drug … , drug-disease, or drug-dietary supplement interactions at the point of care (i.e., at the prescribing … Drug Topics 2003; 6:37. 3. … Identifying drug safety issues: from research to practice. … Adverse drug events in ambulatory care.

167. Behavioral Health Risk Assessment for Pregnant Women Measure Technical Specifications (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/0085-tech-specs.pdf
     January 01, 2012 - following screenings at the first prenatal visit: screening for depression, alcohol use, tobacco use, drug … visit Tobacco use screening Patients who were screened for tobacco use* at the first visit Drug … use (illicit and prescription, over the counter) screening Patients who were screened for any drug … use, prescription drug use and over the counter drug use. … Illicit, Prescription and Over the Counter Drug Use ScreeningRisk Category/Assessment For the purposes

168. Clinical Topic (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/0085textdesc.pdf
     January 01, 2012 - following screenings at the first prenatal visit: screening for depression, alcohol use, tobacco use, drug … visit Tobacco use screening Patients who were screened for tobacco use* at the first visit Drug … use (illicit and prescription, over the counter) screening Patients who were screened for any drug … use, prescription drug use and over the counter drug use. … Illicit, Prescription and Over the Counter Drug Use ScreeningRisk Category/Assessment For the purposes

169. Ø RESOURCE 2C: Possible Methods for Evaluating Antibiotic Use | Agency for Healthcare Research and Quality
     www.ahrq.gov/hai/patient-safety-resources/cdiff-toolkit/cdiffl2tools2c.html
     September 01, 2012 - Monitoring Potential References Defined daily dose (DDD)* Average maintenance dose per day for a drug … World Health Organization Collaborating Centre for Drug Statistics Methodology. … International language for drug utilization research. … Measurement of adult antibacterial drug use in 130 U.S. hospitals: comparison of defined daily dose and

170. Final Progress Report: Cardio-HIT Phase II (pdf file)
     www.ahrq.gov/sites/default/files/2024-12/kmetik-otoole-report.pdf
     January 01, 2024 - intolerance - 19.3%; o drug allergy - 16.2%; o drug interaction - 1.4% … intolerance – 5.7%; o drug allergy – 8.7%; o drug interaction - 0.0% … on the myalgia severity and CAD risk, or may opt for another drug from the same class. … allergy, drug interaction, and drug intolerance. … receive the drug with no reason provided.

171. Declines in Hospital-Acquired Conditions (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/data/infographics/hac_rates_2019-updated.pdf
     January 01, 2019 - Hospital- Acquired Conditions National efforts to reduce hospital-acquired conditions such as adverse drug … Adverse Drug Events -28% CAUTI* -5% CLABSI+ -6% Clostridioides difficile Infections -37%

172. Declines in Hospital-Acquired Conditions (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/data/infographics/hac-rates-2019-updated.pdf
     January 01, 2019 - Hospital- Acquired Conditions National efforts to reduce hospital-acquired conditions such as adverse drug … Adverse Drug Events -28% CAUTI* -5% CLABSI+ -6% Clostridioides difficile Infections -37%

173. Declines in Hospital-Acquired Conditions (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/data/infographics/hac_rates_2019.pdf
     January 01, 2019 - Hospital- Acquired Conditions National efforts to reduce hospital-acquired conditions such as adverse drug … Adverse Drug Events -28% CAUTI* -5% CLABSI+ -6% Clostridioides difficile Infections

174. Declines in Hospital-Acquired Conditions | Agency for Healthcare Research and Quality
     www.ahrq.gov/data/infographics/hac-rates_2019.html
     July 01, 2020 - 11.1 MB) Text Description: National efforts to reduce hospital-acquired conditions such as adverse drug … Specific rates are: Adverse drug events: 28% decrease. CAUTI: 5% decrease. CLABSI: 6% decrease.

175. Ncinqtobaccousehelp-References (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/NCINQTobaccoUseHelp-References.pdf
     August 01, 2012 - CHIP-Program-Information/By-Topic/Early-Periodic-Screening-Diagnosis-Treatment.html National Institute on Drug … Screening for Drug Use in General Medical Settings: A Quick Reference Guide. NIH Pub No. 09-7384. … National Survey on Drug Use and Health (NSDUH). 2010 National Survey on Drug Use and Health data.

176. Fallpxtool3I (doc file)
     www.ahrq.gov/sites/default/files/wysiwyg/professionals/systems/hospital/fallpxtoolkit/fallpxtool3i.docx
     January 01, 2012 - committee or pharmacy department for formulary drugs within the American Hospital Formulary Service drug … adjustment for renal function or disease state, overuse of medications, IV access Laboratory Therapeutic drug

177. Agency for Healthcare Research and Quality
     www.ahrq.gov/research/findings/studies/index.html?page=337
     January 01, 2024 - Pharmacoepidemiol Drug Saf 2017 Mar;26(3):310-19. doi: 10.1002/pds.4126. . … This paper comments on the variety of drug treatment options for patients with type 2 diabetes. … , Nelson SD , Hines L Information needs for making clinical recommendations about potential drug-drug … understand the information needs and work practices of specialists who search and synthesize potential drug-drug … Information needs for making clinical recommendations about potential drug-drug interactions: a synthesis

178. Agency for Healthcare Research and Quality
     www.ahrq.gov/research/findings/studies/index.html?page=349
     January 01, 2024 - This article focuses on recommendations from the Adverse Drug Events (ADE) Action Plan to help guide … Keywords: Prevention, Opioids, Patient Safety, Ambulatory Care and Surgery, Adverse Drug Events (ADE … Personnel, Health Services Research (HSR), Outcomes Cho I , Lee JH , Choi J National rules for drug-drug … This study investigated the potential impact of Korean national drug-drug interactions (DDI) rules in … National rules for drug-drug interactions: are they appropriate for tertiary hospitals?

179. ADHD Behavior Therapy References (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-references.pdf
     August 12, 2012 - Silver Spring, MD: Food and Drug Administration, Center for Drug Evaluation and Research; 2004. … Silver Spring, MD: Food and Drug Administration, Center for Drug Evaluation and Research; 2004. … Mortality associated with attention- deficit hyperactivity disorder (ADHD) drug treatment: a retrospective … Drug Saf; 2009;32(11):1089-1110 McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. … Drug Saf. 2009;32(11):1089-1110 McGoey KE, DuPaul GJ, Haley E, Shelton TL.

180. References (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-88-references.pdf
     August 12, 2012 - Silver Spring, MD: Food and Drug Administration, Center for Drug Evaluation and Research; 2004. … Silver Spring, MD: Food and Drug Administration, Center for Drug Evaluation and Research; 2004. … Mortality associated with attention- deficit hyperactivity disorder (ADHD) drug treatment: a retrospective … Drug Saf; 2009;32(11):1089-1110 McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. … Drug Saf. 2009;32(11):1089-1110 McGoey KE, DuPaul GJ, Haley E, Shelton TL.